

Fundamental and intensive care of acute pancreatitis

Morihisa Hirota · Tadahiro Takada · Nobuya Kitamura · Tetsuhide Ito · Koichi Hirata · Masahiro Yoshida · Toshihiko Mayumi · Keisho Kataoka · Kazunori Takeda · Miho Sekimoto · Masahiko Hirota · Yasutoshi Kimura · Keita Wada · Hodaka Amano · Toshifumi Gabata · Shinju Arata · Masamichi Yokoe · Seiki Kiriyaama

Received: 1 August 2009 / Accepted: 1 September 2009 / Published online: 12 December 2009
© Japanese Society of Hepato-Biliary-Pancreatic Surgery and Springer 2009

Abstract Patients who have been diagnosed as having acute pancreatitis should be, on principle, hospitalized. Crucial fundamental management is required soon after a diagnosis of acute pancreatitis has been made and includes

monitoring of the conscious state, the respiratory and cardiovascular system, the urinary output, adequate fluid replacement and pain control. Along with such management, etiologic diagnosis and severity assessment should be conducted. Patients with a diagnosis of severe acute pancreatitis should be transferred to a medical facility where intensive respiratory and cardiovascular management as well as interventional treatment, blood purification

This article is based on the studies first reported in the JPN guidelines for the management of acute pancreatitis. 3rd ed. JPN Guidelines 2010 (in Japanese). Tokyo: Kanehara; 2009.

Morihisa Hirota (✉)
Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryō, Aoba, Sendai 980-8574, Japan
e-mail: morihirota@mail.tains.tohoku.ac.jp

T. Takada · K. Wada · H. Amano
Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan

N. Kitamura
Department of Emergency and Critical Care Medicine, Kimitsu Chuo Hospital, Chiba, Japan

T. Ito
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

K. Hirata · Y. Kimura
Department of Surgical Oncology and Gastroenterological Surgery, Sapporo Medical University Graduate School of Medicine, Sapporo, Japan

M. Yoshida
Department of Hemodialysis and Surgery, Clinical Research Center Kaken Hospital, International University of Health and Welfare, Chiba, Japan

T. Mayumi
Department of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan

K. Kataoka
Otsu Municipal Hospital, Otsu, Japan

K. Takeda
Department of Surgery, National Hospital Organization Sendai Medical Center, Sendai, Japan

M. Sekimoto
Department of Healthcare Economics and Quality Management, Kyoto University Graduate School of Medicine, Kyoto, Japan

Masahiko Hirota
Department of Surgery, Kumamoto Regional Medical Center, Kumamoto, Japan

T. Gabata
Department of Radiology, Graduate School of Medical Science, Kanazawa University, Ishikawa, Japan

S. Arata
Critical Care and Emergency Center, Yokohama City University Medical Center, Yokohama, Japan

M. Yokoe
General Internal Medicine, Japanese Red Cross Society Nagoya Daini Hospital, Nagoya, Japan

S. Kiriyaama
Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan

therapy and nutritional support are available. The disease condition in acute pancreatitis changes every moment and even symptoms that are mild at the time of diagnosis may become severe later. Therefore, severity assessment should be conducted repeatedly at least within 48 h following diagnosis. An adequate dose of fluid replacement is essential to stabilize cardiovascular dynamics and the dose should be adjusted while assessing circulatory dynamics constantly. A large dose of fluid replacement is usually required in patients with severe acute pancreatitis. Prophylactic antibiotic administration is recommended to prevent infectious complications in patients with severe acute pancreatitis. Although the efficacy of intravenous administration of protease inhibitors is still a matter of controversy, there is a consensus in Japan that a large dose of a synthetic protease inhibitor should be given to patients with severe acute pancreatitis in order to prevent organ failure and other complications. Enteral feeding is superior to parenteral nutrition when it comes to the nutritional support of patients with severe acute pancreatitis. The JPN Guidelines recommend, as optional continuous regional arterial infusion and blood purification therapy.

Keywords Acute pancreatitis · Guidelines · Prophylactic antibiotics · Nutritional support · Protease inhibitor

Introduction

Acute pancreatitis is potentially a fatal disease and its mortality rate is 2.1–7.8%. In 10–20% of patients with acute pancreatitis, the disease becomes severe and the mortality rate associated with acute pancreatitis increases up to 14–25% if the disease is aggravated [1]. The prognosis of acute pancreatitis is determined by two factors including organ failure and pancreatic necrosis.

Patients with a diagnosis of acute pancreatitis should be hospitalized. Initial treatment should be started as soon as possible. Adequate respiratory and cardiovascular monitoring is crucial involving the conscious state, temperature, pulse rate, blood pressure, urinary output, respiratory frequency, and oxygen saturation. Initial treatment and adequate monitoring should be continued while patients are being transferred from the emergency room to a sick ward and from a clinic to a general hospital. Initial treatment includes fasting, adequate dose of fluid replacement and sufficient pain relief. Along with the etiologic diagnosis of acute pancreatitis, severity assessment of acute pancreatitis should be conducted based on the severity scoring system of acute pancreatitis of the Japanese Ministry of Health, Labour, and Welfare (2008). Acute pancreatitis can become severe even if it is mild at the initial visit of a

patient, so repeated severity assessment is crucial. Strict respiratory and cardiovascular management is required in patients with a diagnosis of severe acute pancreatitis, so transference to a medical facility should be considered where intensive care, interventional treatment, blood purification therapy and nutritional support are available. Prophylactic antibiotic administration is recommended for severe acute pancreatitis. There is no consensus on the usefulness of protease inhibitors. Enteral nutrition initiated in the early phase of the disease is superior to intravenous hyperalimentation.

Principles of medical management for acute pancreatitis

Clinical Question (CQ) 1. What are the parameters for adequate dose of fluid replacement as the initial treatment of acute pancreatitis?

Initial fluid replacement should be performed to secure, as its target, stable cardiovascular dynamics with an average blood pressure of more than 65 mmHg as their parameters and the urinary output of 0.5–1 ml/kg/h. (Recommendation A)

In acute pancreatitis, increased vascular permeability and decreased colloid osmotic pressure give rise to a leakage of extracellular fluid into the peripancreas, the retroperitoneum as well as into the abdominal and thoracic cavities, which results in a loss of a large volume of the circulating plasma. Acute cardiovascular disorders brought about in this manner are one of the causes of aggravated initial condition of acute pancreatitis. Therefore, it is mandatory to stabilize the cardiovascular dynamics mainly through replacing a sufficient dose of extracellular fluid initiated in the early phase of the disease.

Calcium and potassium chloride should be replaced if deficiencies arise. Hyperglycemia is managed with insulin as needed. In patients with severe acute pancreatitis, continuous monitoring of central venous pressure or pulmonary wedge pressure, blood gas analysis, and electrolyte measurement is crucial to determining the adequate volume that must be replaced. Oxygen is administered as needed to maintain at least 95% oxygen saturation.

A recent report shows that excessive fluid replacement that has been conducted rapidly and continuously for a long time despite the presence of acute pancreatitis has adverse effects on the prognosis (Level 2b) [2]. When the initial treatment is delivered, repeated assessment of the cardiovascular dynamics should be conducted. Immediately after the start of treatment in particular, the assessment should be conducted every 4–6 h and the transfusion speed should

be adjusted so that an adequate dose of fluid can be achieved.

CQ 2. Is pain control by analgesia necessary?

The pain associated with acute pancreatitis is severe and persistent, so pain control is crucial in the management of acute pancreatitis. (Recommendation A)

The pain associated with acute pancreatitis may cause anxiety in patients and adversely affect their clinical course; this may include respiratory distress, which should be relieved shortly after it develops. The nonnarcotic analgesic buprenorphine has an effect superior to procaine, and, unlike procaine, it does not exacerbate the pathology of acute pancreatitis by including contracting of the sphincter of Oddi (Level 1b) [3]. Pentazocine has an analgesic effect superior to that of procaine (Level 1b) [4]. According to a randomized controlled trial (RCT) comparing metamizole and morphine, the analgesic effect was similar for both agents (Level 2b) [5].

CQ 3. Are nasogastric suction and use of H₂ blockers necessary?

Nasogastric suction is not necessary in mild acute pancreatitis except for cases that are accompanied by paralytic ileus and frequent vomiting. H₂ blockers are not required in an acute pancreatitis except for cases accompanying acute gastric mucosal lesion and hemorrhagic ulcer. On the contrary, H₂ blockers may increase the incidence of complications and prolong the duration of pain. (Recommendation D)

There are no definitive studies in humans to support the opinion that nasogastric suction is useful to the pancreas at rest in patients with acute pancreatitis. RCTs in patients with mild to moderate acute pancreatitis have shown no ameliorating effect of gastric suction on the clinical course by, for example, alleviating pain or shortening the hospital stay (Level 1b) [6–13]. Rather, there are some reports claiming that nasogastric suction may prolong the period of abdominal pain and nausea (Level 1b) [9–12]. The placement of a nasogastric tube in patients with acute pancreatitis is unnecessary unless the disease is associated with paralytic ileus and/or frequent vomiting.

There are no reports suggesting that cimetidine, an H₂ blocker, might ameliorate the clinical course of acute pancreatitis (Level 1b) [12–16]. According to a systematic review (Level 1a) [17], use of cimetidine resulted in a tendency to increase the incidence of complications associated with acute pancreatitis and to prolong the duration of pain. There are no reports of RCTs to date that examined

the efficacy of proton pump inhibitors (PPI) in acute pancreatitis.

However, treatment with an H₂ blocker or a PPI should be considered when a patient with acute pancreatitis develops a stress ulcer or acute gastric mucosal lesion.

CQ 4. Is the prophylactic administration of antibiotics in severe acute pancreatitis effective in preventing bacterial infections?

Prophylactic administration of broad-spectrum antibiotics with good tissue penetration in severe acute pancreatitis is effective in reducing the frequency of complications related to infections. (Recommendation B)

Pancreatic and extrapancreatic infections are a determining factor leading to death in severe acute pancreatitis. The mortality rate of patients with infected pancreatic necrosis or sepsis is extremely high, and antibiotic prophylaxis has been recommended to prevent infectious complications in severe acute pancreatitis. Three RCTs of the antibiotic ampicillin conducted in the 1970s showed that it did not reduce the frequency of infectious complications (Level 1b) [18–20]. A human study investigating pancreatic tissue penetration by antibiotics such as ciprofloxacin, ofloxacin, imipenem, and pefloxacin (pefloxacin) provided sufficient tissue concentration in the pancreas [21]. Four RCTs (Level 1b) [22–25] of the prophylactic effect of antibiotics demonstrated that broad-spectrum antibiotics with good pancreatic tissue penetration decreased the incidence of infectious complications and the mortality rate. RCTs investigating the prophylactic effects of imipenem demonstrated that imipenem decreased the occurrence of infectious pancreatic complications (Level 1b) [26, 27]. Two RCTs (Level 1b) [28, 29] that investigated the prophylactic effects of meropenem also showed a decrease in the occurrence of infectious complications and the occurrence of pancreatic infections, complications, or mortality was similar as that of imipenem [28].

On the other hand, a placebo-controlled, double-blind trial of ciprofloxacin + metronidazole in patients with predicted severe acute pancreatitis showed that prophylactic administration of these antibiotics did not prevent pancreatic infection (Level 1b) [30]. According to an RCT that examined the prophylactic effects of meropenem in patients with necrotizing pancreatitis, the incidence and mortality rates of pancreatic infections and the rate of cases that required surgical intervention were not different from those in a placebo-controlled group (Level 1a) [31].

Meta-analyses (Level 1a) [32–37] concerning these RCTs demonstrated a decrease in the mortality rate associated with the prophylactic use of wide-spectrum

antibiotics with good tissue penetration into the pancreatic tissue [32–35] and in the incidence of infectious complications [33, 34]. On the other hand, there are meta-analyses (Level 1a) [36, 37] showing that no decrease was observed both in the mortality rate and the incidence of infectious complications. The reason for such inconsistent results is the difference in diagnostic criteria from institution to institution. RCTs of higher quality should eventually be conducted for further examination.

Selective digestive decontamination (SDD) has also been reported as a means of antibiotic prophylaxis in severe acute pancreatitis (Level 1b) [38]. Although SDD was reported in the 1980s as a method of preventing respiratory tract infection in patients with multiple trauma [39], only one RCT assessed SDD in severe acute pancreatitis (Level 1b) [38]. In that trial, antibiotics were given orally, enterally, and intravenously, as well as being applied topically to the gums and tracheotomy site. SDD significantly reduced the frequency of infectious pancreatic complications compared with that in the control groups, and multivariate analysis with severity assessment demonstrated a reduced mortality rate for SDD. In principle, SDD offers comprehensive infection management, not only by the enteral administration of nonabsorptive agents but also by the prevention of systemic infection through sterilization of the oral cavity, as well as by intravenous antibiotic administration and continuous surveillance cultures of the oral cavity and rectum.

Although the prophylactic application of broad-spectrum antibiotics reduces the incidence of infectious complications in severe acute pancreatitis, fungal infection in pancreatic necrosis is increasing (Level 2b) [40–45]. The mortality rate of infected pancreatic necrosis complicated by fungal infection is higher than the mortality rate in the absence of fungal infection (Level 2b) [40–45]. A human study reported that the antifungal agent fluconazole had good penetration into pancreatic tissue (Level 2b) [46], and clinical studies have demonstrated that the prophylactic administration of fluconazole reduced the incidence of fungal infection in patients with severe acute pancreatitis (Level 2b) [44–47]. However, there have been no reliable RCTs of the prophylactic administration of antifungal agents in patients with pancreatic necrosis, and the efficacy of antifungal agents has yet to be investigated in an RCT.

CQ 5. Is the continuous infusion of a large dose of protease inhibitors effective in severe acute pancreatitis?

Continuous intravenous infusion of a large dose of protease inhibitors may reduce the mortality rate of severe acute pancreatitis and the frequency of complications in

the early phase of severe acute pancreatitis. (Recommendation C1)

In the 1960s, the protease inhibitor aprotinin was widely used to treat severe acute pancreatitis, but the drug failed to demonstrate clinical efficacy in three RCTs (Level 1b) [48–50]. The efficacy of the synthetic protease inhibitor gabexate mesilate was investigated in five RCTs (Level 1b) [51–55], but a meta-analysis of four of them [51–54] showed no reduction in the frequency of surgical intervention or in the mortality rate, although the incidence of complications was reduced (Level 1a) [56]. However, the remaining RCT (Level 1b) [55], the results of which were published in 2000, showed that continuous intravenous administration of gabexate mesilate (2400 mg/day) for 7 days significantly reduced the frequency of complications and the mortality rate. According to a meta-analysis (Level 1a) [57] of ten RCTs (6 trials of gabexate mesilate [51–53, 55, 58, 59] and 4 trials of aprotinin [49, 50, 60, 61]) reported in 2004, use of protease inhibitors did not lead to a decreased mortality rate in patients with acute pancreatitis. On the other hand, a meta-analysis concerning the data sampled from patients with moderate~severe acute pancreatitis showed that the mortality rate decreased significantly owing to the infusion of protease inhibitors.

Since the efficacy of protease inhibitors in severe acute pancreatitis is still a matter of controversy, their use was classified into recommendation grade “B” in the JPN GL 2007 but it was changed to “C1” in the present edition.

CQ 6. Is enteral nutrition initiated in the early phase of severe acute pancreatitis more useful than intravenous hyperalimentation?

If there is no ileus, enteral nutrition initiated in the early phase of severe acute pancreatitis is superior to intravenous hyperalimentation. (Recommendation B)

Clinical trials of nutritional management in acute pancreatitis have shown that enteral nutrition is more useful than total parenteral nutrition in terms of ability to alleviate the inflammatory response and reduce the incidence of infection, frequency of surgery, and medical costs. A meta-analysis (Level 1a) [62] of six RCTs (263 cases; Level 1b) [63–68]—which compared two methods of nutritional management of acute pancreatitis (total parental nutritional and enteral nutrition)—showed that enteral nutrition reduced the frequency of infection, surgery, and the length of hospital stay. However, there was no difference in the mortality rate or incidence of complications other than infection.

According to an RCT concerning severe pancreatitis (Level 1b) [65], medical costs per capita in patients who underwent enteral nutrition were one-third of those in

patients who underwent intravenous nutrition. A recent RCT has found that the mortality rate of infected pancreatic necrosis and the incidence and mortality rates of multiple organ failure decreased in patients who underwent enteral nutrition compared in those who underwent intravenous nutrition (Level 1b) [69].

Enteral nutrition has been provided through feeding tubes inserted from the ligament of Treitz to the distal jejunum, and the infusion of nutrients into the stomach and duodenum has been avoided because of the possibility of stimulating pancreatic exocrine secretion. However, a report from Glasgow (Level 1b) [70], comparing nasogastric to nasojejunal feeding, found no difference in changes in the Acute Physiology and Chronic Health Evaluation (APACHE) II score, C-reactive protein (CRP) level, visual analogue scale (VAS) pain score, doses of analgesic administered, or mortality rates between the two methods. A recent systematic review has shown that, in terms of safety, nasogastric feeding yielded results as good as did nasojejunal feeding in acute pancreatitis. Further accumulation of cases was considered necessary (Level 1a) [71]. Nasogastric feeding is easier to perform and it is easier to locate the tube than it is to locate a nasojejunal tube. Nasogastric nutrition should be investigated further.

An RCT [72] comparing a group of patients with acute pancreatitis in whom lactic acid bacteria was administered in addition to enteral nutrition and a group in which lactobacillus inactivated by heating was administered showed that the incidence of pancreatic infections was decreased by the addition of lactic acid bacteria (Level 2b). According to reports (Level 1b) [73–76] and a meta-analysis (Level 1a) [77] that examined the survival rate and incidence of the use of glutamine, arginine, omega-3 fatty acid and probiotics besides lactic acid bacteria in addition to enteral nutrition, no improvement was observed in the survival rate compared with a control group and no consistent results were obtained in the incidence of infectious diseases. Furthermore, an RCT (Level 1b) [78] examining the effects of administering probiotic agents enterally in patients with predicted severe acute pancreatitis reported that probiotic administration resulted, not in a decrease in the incidence of infections, but rather an increase in the mortality rate. As yet, there is no conclusion about the merits and demerits of using these agents. Further discussion is needed from now on.

CQ 7. Is regional intra-arterial infusion of protease inhibitors and antibiotics able to reduce the mortality rate and frequency of infectious pancreatic complications?

Intra-arterial local infusion of protease inhibitors and antibiotics in the early phase of the disease may lead to a

decrease in the mortality rate of acute necrotizing pancreatitis and in the frequency of infectious pancreatic complications. (Recommendation C1)

The protease inhibitors used to treat acute necrotizing pancreatitis cannot easily reach the pancreas when administered intravenously and, because of ischemia [79, 80] or impaired microcirculation, they hardly penetrate into pancreatic tissue. Administration through a catheter placed in one of the arteries that supply the inflamed area of the pancreas, however, dramatically increases the tissue concentration of the protease inhibitor. A clinical study of continuous regional arterial infusion (CRAI) of a protease inhibitor and/or an antibiotic demonstrated that CRAI of nafamostat mesilate and imipenem/cilastatin was effective in reducing the mortality rate and preventing the development of pancreatic infection in acute necrotizing pancreatitis (Level 3b) [81]. A nationwide survey of CRAI therapy in acute necrotizing pancreatitis reported that severe pain disappeared in a short period of time after the initiation of CRAI of a protease inhibitor; that the frequency of infected pancreatic necrosis in the group treated with both a protease inhibitor and antibiotic via CRAI was significantly lower than that in the group treated with the protease inhibitor alone; and that the mortality rate was significantly lower in the group in which CRAI of the protease inhibitor was started within 2 days after onset than that in the group in which it was started three or more days after onset (Level 2c) [82]. A multi-center trial conducted recently in Japan using gabexate mesilate and antibiotics compared a group in which CRAI was performed with a group in which CRAI was not performed. The trial found that the duration of abdominal pain and systemic inflammatory response syndrome (SIRS) and the length of hospital stay were shortened. Also, CRP, interleukin 6 (IL6)/interleukin 10 (IL 10) ratio was found to be improved in a shorter time (Level 3b) [83].

A historical study, comparing intravenous administration and CRAI of a protease inhibitor and antibiotic, revealed a significantly higher cumulative survival rate in the CRAI group (Level 4) [84]. In a clinical study in which arterial infusion was performed after confirming, by computed tomography (CT) arteriography, that the drug had reached the site of inflammation in the pancreas, the APACHE II score and the CT severity index were improved in all subjects (Level 4) [85]. CRAI of the protease inhibitor nafamostat also prevented pancreatic necrosis in patients with severe acute pancreatitis associated with nonocclusive mesenteric ischemia (NOMI) (Level 4) [86]. Although the efficacy of CRAI of a protease inhibitor and the optimal timing is still being debated, CRAI therapy is given Recommendation C in the JPN

Guidelines. The usefulness of CRAI of a protease inhibitor should be investigated further.

CQ 8. Is blood purification therapy useful in severe acute pancreatitis?

Continuous blood purification therapy performed in the early phase of severe acute pancreatitis is likely to prevent progression to multiple organ failure. (Recommendation C1)

The activation of proinflammatory cytokines in severe acute pancreatitis is a predominant factor leading to multiple organ failure. Blood purification therapy, particularly continuous hemodiafiltration (CHDF), may inhibit the systemic inflammatory response by removing the humoral mediators. CHDF with a polymethylmethacrylate (PMMA) membrane may remove various cytokines from the bloodstream and is widely used in Japan for blood purification therapy in patients with severe acute pancreatitis complicated by multiple organ failure. A national survey of the usefulness of CHDF in severe acute pancreatitis suggested that it may prevent the progress of multiple organ failure (Level 4) [87]. It is also reported that CHDF using PMMA is useful in treating intra-abdominal hypertension (IHA) and abdominal compartment syndrome (ACS) (Level 4) [88].

However, its ability to reduce the mortality rate is still unknown.

References

1. Sekimoto M, Shikata S, Takada T, et al. Changes in management of acute pancreatitis before and after the publication of evidence-based practice guidelines in 2003. *J Hepatobiliary Pancreat Surg* 2009. doi:10.1007/s00534-009-0212-5.
2. Mao EQ, Tang YQ, Fei J, Qin S, Wu J, Li L, et al. Fluid therapy for severe acute pancreatitis in acute response stage. *Chin Med J*. 2009;122:169–73.
3. Jakobs R, Adamek MU, von Bubnoff AC, Riemann JF. Buprenorphine or procaine for pain relief in acute pancreatitis. A prospective randomized study. *Scand J Gastroenterol*. 2000;35:1319–23.
4. Kahl S, Zimmermann S, Pross M, Schulz HU, Schmidt U, Malfertheiner P. Procaine hydrochloride fails to relieve pain in patients with acute pancreatitis. *Digestion*. 2004;69:5–9.
5. Peiró AM, Martínez J, Martínez E, de Madaria E, Llorens P, Horga JF, et al. Efficacy and tolerance of metamizole versus morphine for acute pancreatitis pain. *Pancreatol*. 2008;8:25–9.
6. Levant JA, Secrist DM, Resin H, Sturdevant RA, Guth PH. Nasogastric suction in the treatment of alcoholic pancreatitis. A controlled study. *JAMA*. 1974;229:51–2.
7. Naeije R, Salingret E, Clumeck N, De Troyer A, Devis G. Is nasogastric suction necessary in acute pancreatitis? *Br Med J*. 1978;2:659–60.
8. Field BE, Hepner GW, Shabot MM, Schwartz AA, State D, Worthen N, et al. Nasogastric suction in alcoholic pancreatitis. *Dig Dis Sci*. 1979;24:339–44.
9. Fuller RK, Loveland JP, Frankel MH. An evaluation of the efficacy of nasogastric suction treatment in alcoholic pancreatitis. *Am J Gastroenterol*. 1981;75:349–53.
10. Louidice TA, Lang J, Mehta H, Banta L. Treatment of acute alcoholic pancreatitis: the roles of cimetidine and nasogastric suction. *Am J Gastroenterol*. 1984;79:553–8.
11. Sarr MG, Sanfey H, Cameron JL. Prospective, randomized trial of nasogastric suction in patients with acute pancreatitis. *Surgery*. 1986;100:500–4.
12. Navarro S, Ros E, Aused R, García Pugés M, Piqué JM, et al. Comparison of fasting, nasogastric suction and cimetidine in the treatment of acute pancreatitis. *Digestion*. 1984;30:224–30.
13. Goff JS, Feinberg LE, Brugge WR. A randomized trial comparing cimetidine to nasogastric suction in acute pancreatitis. *Dig Dis Sci*. 1982;27:1085–8.
14. Meshkinpour H, Molinari MD, Gardner L, Berl JE, Hoehler FK. Cimetidine in the treatment of acute alcoholic pancreatitis. A randomized, double-blind study. *Gastroenterology*. 1979;77:687–90.
15. Broe PJ, Zinner MJ, Cameron JL. A clinical trial of cimetidine in acute pancreatitis. *Surg Gynecol Obstet*. 1982;154:13–6.
16. Louidice TA, Lang J, Mehta H, Banta L. Treatment of acute alcoholic pancreatitis: the role of cimetidine and nasogastric suction. *Am J Gastroenterol*. 1984;9:553–8.
17. Morimoto T, Noguchi Y, Sakai T, Shimbo T, Fukui T. Acute pancreatitis and the role of histamine-2 receptor antagonists: a meta-analysis of randomized controlled trials of cimetidine. *Eur J Gastroenterol Hepatol*. 2002;14:679–86.
18. Craig RM, Dordal E, Myles L. The use of ampicillin in acute pancreatitis. *Ann Intern Med*. 1975;83:831–2.
19. Finch WT, Sawyers JL, Schenker S. A prospective study to determine the efficacy of antibiotics in acute pancreatitis. *Ann Surg*. 1976;183:667–71.
20. Howes R, Zuidema GD, Cameron JL. Evaluation of prophylactic antibiotics in acute pancreatitis. *J Surg Res*. 1975;18:197–200.
21. Büchler M, Malfertheiner P, Friess H, Isenmann R, Vanek E, Grimm H, et al. Human pancreatic tissue concentration of bactericidal antibiotics. *Gastroenterology*. 1992;103:1902–8.
22. Pederzoli P, Bassi C, Vesentini S, Campedelli A. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. *Surg Gynecol Obstet*. 1993;176:480–3.
23. Sainio V, Kempainen E, Puolakkainen P, Taavitsainen M, Kivisaari L, Valtonen V, et al. Early antibiotic treatment in acute necrotizing pancreatitis. *Lancet*. 1995;346:663–7.
24. Delcenserie R, Yzet T, Ducroix JP. Prophylactic antibiotics in treatment of severe acute alcoholic pancreatitis. *Pancreas*. 1996;13:198–201.
25. Schwarz M, Isenmann R, Meyer H, Beger HG. Antibiotic use in necrotizing pancreatitis. Results of a controlled study. *Dtsch Med Wochenschr*. 1997;122:356–61.
26. Nordback I, Sand J, Saaristo R, Paajanen H. Early treatment with antibiotics reduces the need for surgery in acute necrotizing pancreatitis—a single-center randomized study. *J Gastrointest Surg*. 2001;5:113–8.
27. Rokke O, Harbitz TB, Liljedal J, Pettersen T, Fetvedt T, Heen LØ, et al. Early treatment of severe pancreatitis with imipenem: a prospective randomized clinical trial. *Scand J Gastroenterol*. 2007;42:771–6.
28. Manes G, Rabitti PG, Menchise A, Riccio E, Balzano A, Uomo G. Prophylaxis with meropenem of septic complications in acute pancreatitis: a randomized, controlled trial versus imipenem. *Pancreas*. 2003;27:e79–83.

29. Manes G, Uomo I, Menchise A, Rabitti PG, Ferrara EC, Uomo G. Timing of antibiotic prophylaxis in acute pancreatitis: a controlled randomized study with meropenem. *Am J Gastroenterol.* 2006;101:1348–53.
30. Isenmann R, Runzi M, Kron M, Kahl S, Kraus D, Jung N, et al. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial. *Gastroenterology.* 2004;126:997–1004.
31. Dellinger EP, Tellado JM, Soto NE, Ashley SW, Barie PS, Dugernier T, et al. Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study. *Ann Surg.* 2007;245:674–83.
32. Golub R, Siddiqi F, Pohl D. Role of antibiotics in acute pancreatitis: a meta-analysis. *J Gastrointest Surg.* 1998;2:496–503.
33. Sharma VK, Howden CW. Prophylactic antibiotic administration reduces sepsis and mortality in acute necrotizing pancreatitis: a meta-analysis. *Pancreas.* 2001;22:28–31.
34. Villatoro E, Larvin M, Bassi C. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. *Cochrane Database Syst Rev.* 2003;19:CD002941.
35. Villatoro E, Bassi C, Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. *Cochrane Database Syst Rev.* 2006;4:CD002941.
36. Bai Y, Gao J, Zou D, Li ZS. Prophylactic antibiotics cannot reduce infected pancreatic necrosis and mortality in acute necrotizing pancreatitis: evidence from a meta-analysis of randomized controlled trials. *Am J Gastroenterol.* 2008;103:104–10.
37. de Vries AC, Besselink MG, Buskens E, Ridwan BU, Schipper M, van Erpecum KJ, et al. Randomized controlled trials of antibiotic prophylaxis in severe acute pancreatitis: relationship between methodological quality and outcome. *Pancreatol.* 2007;7:531–8.
38. Luiten EJ, Hop WC, Lange JF, Bruining HA. Controlled clinical trial of selective decontamination for the treatment of severe acute pancreatitis. *Ann Surg.* 1995;222:57–65.
39. Stoutenbeek CP, van Saene HK, Miranda DR, Zandstra DF. The effect of selective decontamination of the digestive tract on colonization and infection rate in multiple trauma patients. *Intensive Care Med.* 1984;10:185–92.
40. Grewe M, Tsiotos GG, Luque de-Leon E, Sarr MG. Fungal infection in acute necrotizing pancreatitis. *J Am Coll Surg.* 1999;188:408–14.
41. Gotinger P, Wamser P, Barlan M, Sautner T, Jakesz R, Fugger R. Candida infection of local necrosis in severe acute pancreatitis is associated with increased mortality. *Shock.* 2000;14:320–3.
42. Gloor B, Muller CA, Wormi M, Stahel PF, Redaelli C, Uhl W, et al. Pancreatic infection in severe pancreatitis. The role of fungus and multiresistant organisms. *Arch Surg.* 2001;136:592–6.
43. Isenmann R, Schwarz M, Rau B, Trautmann M, Schober W, Med C, et al. Characteristics of infection with candida species in patients with necrotizing pancreatitis. *World J Surg.* 2002;25:372–6.
44. De Waele JJ, Vogelaers D, Blot S, Colardyn F. Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. *Clin Infect Dis.* 2003;37:208–13.
45. Conner S, Alexakis N, Neal T, Raraty M, Ghaneh P, Evans J, et al. Fungal infection but not type of bacterial infection is associated with a high mortality in primary and secondary infected pancreatic necrosis. *Dig Surg.* 2004;21:297–304.
46. Shrikhande S, Friess H, Issengger C, Martignoni M, Yong H, Gloor B, et al. Fluconazole penetration into the pancreas. *Antimicrob Agents Chemother.* 2000;44:2569–71.
47. He YM, Lv XS, Ai ZL, Liu ZS, Qian Q, Sun Q, et al. Prevention and therapy of fungal infection in severe acute pancreatitis: a prospective clinical study. *World J Gastroenterol.* 2003;9:2619–21.
48. Skyring A, Singer A, Tornya P. Treatment of acute pancreatitis with Trasylol: report of a controlled therapeutic trial. *Br Med J.* 1965;5462:627–9.
49. Baden H, Jordal K, Lund F, Zachariae F. A double-blind controlled clinical trial of Trasylol. Preliminary results in acute pancreatitis and in prophylaxis against postoperative pancreatitis. *Acta Chir Scand Suppl.* 1967;378:97–102.
50. Imrie CW, Benjamin IS, Ferguson JC, McKay AJ, Mackenzie I, O'Neill J, et al. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. *Br J Surg.* 1978;65:337–41.
51. Valderrama R, Perez-Mateo M, Navarro S, Vázquez N, Sanjosé L, Adrián MJ, et al. Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. *Digestion.* 1992;51:65–70.
52. Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis. *Pancreas.* 1987;2:698–700.
53. Buchler M, Malfertheiner P, Uhl W, Schölmerich J, Stöckmann F, Adler G, et al. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. *Gastroenterology.* 1993;104:1165–70.
54. Derveniz C, Johnson CD, Bassi C, Bradley E, Imrie CW, McMahon MJ, et al. Diagnosis, objective assessment of severity, and management of acute pancreatitis. Santorini Consensus Conference report. *Int J Pancreatol.* 1999;25:195–210.
55. Chen HM, Chen JC, Hwang TL, Jan YY, Chen MF. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. *Hepatogastroenterology.* 2000;47:1147–50.
56. Andriulli A, Leandro G, Clemente R, Festa V, Caruso N, Annese V, et al. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. *Aliment Pharmacol Ther.* 1998;12:237–45.
57. Seta T, Noguchi Y, Shimada T, Shikata S, Fukui T. Treatment of acute pancreatitis with protease inhibitors: a meta-analysis. *Eur J Gastroenterol Hepatol.* 2004;16:1287–93.
58. Freise J, Melzer P, Schmidt FW, Horbach L. Gabexate mesilate in the treatment of acute pancreatitis. Results of a Hannover multicenter double-blind study with 50 patients. *Z Gastroenterol.* 1986;24:200–11.
59. Goebell H. Multicenter double-blind study of gabexate mesilate (Foy) given intravenously in low dose in acute pancreatitis. *Digestion.* 1988;40:73. (abstract).
60. Trapnell JE, Rigby CC, Talbot CH, Duncan EH. A controlled trial of Trasylol in the treatment of acute pancreatitis. *Br J Surg.* 1974;61:177–82.
61. Bachrach WH, Schild PD. A double-blind study of Trasylol in the treatment of pancreatitis. *Ann N Y Acad Sci.* 1968;146:580–92.
62. Marik PE, Zaloga GP. Meta-analysis of parenteral nutrition versus enteral nutrition in patients with acute pancreatitis. *BMJ.* 2004;328:1407–12.
63. McClave SA, Greene LM, Snider HL, Makk LJ, Cheadle WG, Owens NA, et al. Comparison of the safety of early enteral vs parenteral nutrition in mild acute pancreatitis. *JPEN J Parenter Enteral Nutr.* 1997;21:14–20.
64. Windsor AC, Kanwar S, Li AG, Barnes E, Guthrie JA, Spark JJ, et al. Compared with parenteral nutrition, enteral feeding attenuates the acute phase response and improves disease severity in acute pancreatitis. *Gut.* 1998;42:431–5.
65. Kalfarentzos F, Kehagias J, Mead N, Kokkinis K, Gogos CA. Enteral nutrition is superior to parenteral nutrition in severe acute pancreatitis: results of a randomized prospective trial. *Br J Surg.* 1997;84:1665–9.

66. Olah A, Pardavi G, Belagyi T, Nagy A, Issekutz A, Mohamed GE. Early nasojejunal feeding in acute pancreatitis is associated with a lower complication rate. *Nutrition*. 2002;18:259–62.
67. Abou-Assi S, Craig K, O'Keefe SJ. Hypocaloric jejunal feeding is better than total parenteral nutrition in acute pancreatitis: results of a randomized comparative study. *Am J Gastroenterol*. 2002;97:2255–62.
68. Gupta R, Patel K, Calder PC, Yaqoob P, Primrose JN, Johnson CD. A randomised clinical trial to assess the effect of total enteral and parenteral nutritional support on metabolic, inflammatory and oxidative markers in patients with predicted severe acute pancreatitis (APACHE II \geq 6). *Pancreatology*. 2003;3:406–13.
69. Petrov MS, Kukosh MV, Emelyanov NV. A randomized controlled trial of enteral versus parenteral feeding in patients with predicted severe acute pancreatitis shows a significant reduction in mortality and in infected pancreatic complications with total enteral nutrition. *Dig Surg*. 2006;23(5–6):336–44.
70. Eatock FC, Chong P, Menezes N, Murray L, McKay CJ, Carter CR, et al. A randomized study of early nasogastric versus nasojejunal feeding in severe acute pancreatitis. *Am J Gastroenterol*. 2005;100:432–9.
71. Petrov MS, Correia MI, Windsor JA. Nasogastric tube feeding in predicted severe acute pancreatitis. A systematic review of the literature to determine safety and tolerance. *JOP*. 2008;9(4):440–8.
72. Olah A, Belagyi T, Issekutz A, Gamal ME, Bengmark S. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. *Br J Surg*. 2002;89:1103–7.
73. Fuentes-Orozco C, Cervantes-Guevara G, Muciño-Hernández I, López-Ortega A, Ambriz-González G, Gutiérrez-de-la-Rosa JL, et al. L-Alanyl-L-glutamine-supplemented parenteral nutrition decreases infectious morbidity rate in patients with severe acute pancreatitis. *JPEN J Parenter Enteral Nutr*. 2008;32(4):403–11.
74. Wang X, Li W, Li N, Li J. Omega-3 fatty acids-supplemented parenteral nutrition decreases hyperinflammatory response and attenuates systemic disease sequelae in severe acute pancreatitis: a randomized and controlled study. *JPEN J Parenter Enteral Nutr*. 2008;32(3):236–41.
75. Pearce CB, Sadek SA, Walters AM, Goggin PM, Somers SS, Toh SK, et al. A double-blind, randomised, controlled trial to study the effects of an enteral feed supplemented with glutamine, arginine, and omega-3 fatty acid in predicted acute severe pancreatitis. *JOP*. 2006;7(4):361–71.
76. Oláh A, Belágyi T, Pótó L, Romics L Jr, Bengmark S. Synbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. *Hepatogastroenterology*. 2007;54(74):590–4.
77. Petrov MS, Atduev VA, Zagainov VE. Advanced enteral therapy in acute pancreatitis: is there a room for immunonutrition? A meta-analysis. *Int J Surg*. 2008;6(2):119–24.
78. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2008;371(9613):651–9.
79. Inoue K, Hirota M, Kimura Y, Kuwata K, Ohmuraya M, Ogawa M. Further evidence for endothelin as an important mediator of pancreatic and intestinal ischemia in severe acute pancreatitis. *Pancreas*. 2003;26:218–23.
80. Takeda K, Mikami Y, Fukuyama S, Egawa S, Sunamura M, Ishibashi T, et al. Pancreatic ischemia associated with vasospasm in the early phase of human acute necrotizing pancreatitis. *Pancreas*. 2005;30:40–9.
81. Takeda K, Matsuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. *Am J Surg*. 1996;171:394–8.
82. Takeda K, Matsuno S, Ogawa M, Watanabe S, Atomi Y. Continuous regional arterial infusion (CRAI) therapy reduces the mortality rate of acute necrotizing pancreatitis: result of a cooperative national survey in Japan. *J Hepatobiliary Pancreat Surg*. 2001;8:216–20.
83. Ino Y, Arita Y, Akashi T, Kimura T, Igarashi H, Oono T, et al. Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis. *World J Gastroenterol*. 2008;14:6382–7.
84. Imaizumi H, Kida M, Nishimaki H, Okuno J, Kataoka Y, Kida Y, et al. Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. *Pancreas*. 2004;4:369–73.
85. Anai H, Sakaguchi H, Uchida H, Matsuo N, Tanaka T, Yoshioka T, et al. Continuous arterial infusion therapy for severe acute pancreatitis: correlation between CT arteriography and therapeutic effect. *J Vasc Interv Radiol*. 1999;10:1335–42.
86. Hirota M, Inoue K, Kimura Y, Mizumoto T, Kuwata k, Ohmuraya M, et al. Non-occlusive mesenteric ischemia and its associated intestinal gangrene in acute pancreatitis. *Pancreatology*. 2003;3:316–22.
87. Matsuno S, Ogawa M, Watanabe S, Atomi Y. National survey for the efficacy of blood purification therapy in severe acute pancreatitis in Japan. Annual report of the Research Committee of Intractable Diseases of the Pancreas. 1998. p. 36–41.
88. Oda S, Hirasawa H, Shiga H, Matsuda K, Nakamura M, Watanabe E, et al. Management of intra-abdominal hypertension in patients with severe acute pancreatitis with continuous hemodiafiltration using a polymethyl methacrylate membrane hemofilter. *Ther Apher*. 2005;9:335–61.